Last edition
News about "Lantern Pharma "
FDA Grants Orphan Drug Designation to LP-284 of Lantern Pharma
The designation marks the third FDA orphan status for LP-284 and the sixth across Lantern Pharma’s AI-driven oncology pipeline, strengthening the programme’s development momentum in soft tissue sarcomas, a rare cancer segment with significant unmet need and a growing global market.
Lantern Pharma | 21/01/2026 | By News Bureau | 120
The technology has demonstrated to-date exceptional performance in predicting BBB permeability across a wide range of chemical compounds, processing up to 100,000 molecules per hour with industry-leading accuracy.
Lantern Pharma | 20/02/2025 | By Aishwarya | 247
Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer
The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.
Lantern Pharma | 28/01/2025 | By Aishwarya | 524
The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.
Lantern Pharma | 10/12/2024 | By Aishwarya | 265
Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC
Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
Lantern Pharma | 23/04/2024 | By Aishwarya | 320
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy